Compare NGEN & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGEN | ARMP |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Canada | United States |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 383.7M |
| IPO Year | N/A | 1996 |
| Metric | NGEN | ARMP |
|---|---|---|
| Price | $4.19 | $12.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 196.4K | 37.7K |
| Earning Date | 04-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.51 | $1.11 |
| 52 Week High | $5.93 | $13.75 |
| Indicator | NGEN | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 63.84 |
| Support Level | $3.65 | $5.14 |
| Resistance Level | $4.52 | $13.75 |
| Average True Range (ATR) | 0.28 | 1.20 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 54.31 | 82.97 |
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.